Figure 1:
Tumor Types and Number of Prior Therapies in the Tissue Agnostic Efficacy Population (N=41). Source: U.S. Food and Drug Administration. sNDA Multi-disciplinary Review and Evaluation and Approval Package: RETEVMO (selpercatinib).19
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.